Last updated: September 8, 2026
Etelcalcetide, marketed by Amgen as Parsabiv, is an intravenous calcimimetic approved in the United States for secondary hyperparathyroidism in adults with chronic kidney disease receiving hemodialysis. Its commercial position depends on dialysis-center administration, reimbursement economics, and competition from oral cinacalcet, including generic versions. Etelcalcetide has a differentiated delivery model but operates in a mature, price-sensitive nephrology market.
What is etelcalcetide and how does it work?
Etelcalcetide is a synthetic peptide calcimimetic that activates the calcium-sensing receptor on parathyroid cells. Activation reduces parathyroid hormone secretion and lowers serum parathyroid hormone, calcium, and phosphorus levels.
The FDA approved Parsabiv on February 7, 2017, for secondary hyperparathyroidism in adults with chronic kidney disease on hemodialysis. The drug is administered intravenously at the end of hemodialysis by dialysis-center personnel, generally three times per week. The recommended starting dose is 5 mg, with titration based on parathyroid hormone and corrected serum calcium levels. [1]
Etelcalcetide competes primarily with:
- Generic cinacalcet tablets.
- Sensipar, Amgen’s former branded cinacalcet product.
- Vitamin D analogues and active vitamin D therapies.
- Surgical parathyroidectomy for difficult-to-control disease.
Its main clinical and commercial distinction is intravenous delivery during dialysis rather than patient-administered oral dosing.
How large is the etelcalcetide market?
The addressable market is the global hemodialysis population with secondary hyperparathyroidism. The market is structurally concentrated because treatment decisions are influenced by dialysis operators, nephrologists, formularies, and government reimbursement systems.
The commercial market has several limiting factors:
- Nearly all use occurs in a chronic kidney disease population treated in dialysis facilities.
- Drug selection is sensitive to bundled reimbursement and dialysis-center purchasing contracts.
- Oral cinacalcet has broad prescribing familiarity and generic availability.
- Etelcalcetide requires intravenous administration, which limits outpatient use outside dialysis.
- Treatment is chronic, but dose intensity varies with disease control and calcium levels.
The U.S. dialysis population creates the largest commercial opportunity for Parsabiv. Japan and selected European markets also provide access, but regulatory labels, reimbursement, and dialysis practices differ by jurisdiction.
What has been the financial trajectory of Parsabiv?
Parsabiv has followed a launch-ramp and maturation pattern rather than the rapid expansion typical of primary-care drugs. Early commercial growth reflected adoption by dialysis providers and conversion from oral calcimimetic treatment. Later performance depended on formulary placement, reimbursement, dosing persistence, and price competition.
Amgen reports Parsabiv as a product within its general medicines portfolio and provides less granular disclosure than it does for major products such as Prolia, Repatha, Enbrel, or Otezla. Public filings do not separately disclose Parsabiv’s product-level gross margin, operating profit, patient count, or detailed geographic revenue. [2, 3]
| Financial factor |
Effect on Parsabiv |
| Launch timing |
U.S. launch began in 2017 |
| Revenue pattern |
Initial growth followed by mature-market stabilization |
| Prescription channel |
Dialysis facilities and institutional purchasing |
| Pricing power |
Constrained by bundled reimbursement and generic cinacalcet |
| Manufacturing economics |
Peptide production and sterile injectable supply requirements |
| Commercial cost base |
Focused nephrology sales, medical education, and account contracting |
| Main financial risk |
Substitution by low-cost oral cinacalcet |
| Main support |
Administration during dialysis and controlled adherence |
The product’s economics are likely stronger at facilities that value direct administration and adherence control. Oral cinacalcet can be less predictable when patients miss doses, experience gastrointestinal adverse effects, or have difficulty managing complex medication schedules. Parsabiv can capture value from that operational advantage, but the dialysis facility must absorb or recover the drug cost.
How does etelcalcetide compare with cinacalcet?
Etelcalcetide and cinacalcet have the same broad therapeutic objective but different delivery systems and purchasing economics.
| Attribute |
Etelcalcetide |
Cinacalcet |
| Brand |
Parsabiv |
Sensipar, with generic versions |
| Route |
Intravenous |
Oral |
| Administration |
At the end of hemodialysis |
Patient-administered |
| Dosing frequency |
Generally three times weekly |
Usually daily |
| Patient adherence |
Controlled by dialysis staff |
Dependent on patient adherence |
| Generic competition |
Limited by peptide and injectable complexity |
Established generic competition |
| Main commercial buyer |
Dialysis provider or facility system |
Pharmacy, payer, or patient |
| Key adverse-effect concern |
Hypocalcemia |
Hypocalcemia and gastrointestinal effects |
| Best commercial argument |
Reliable administration and dialysis workflow integration |
Lower acquisition cost and prescribing familiarity |
Generic cinacalcet has materially changed the competitive environment. A dialysis organization can favor generic tablets where acquisition cost is the overriding consideration. Parsabiv is better positioned where treatment administration, adherence, and parathyroid hormone control are prioritized.
What patents protect etelcalcetide?
Etelcalcetide’s intellectual-property position includes composition-of-matter, peptide-related, formulation, manufacturing, and therapeutic-use patent concepts. The underlying estate originated with KAI Pharmaceuticals, which Amgen acquired in 2015. Amgen paid approximately $315 million upfront, with potential milestone payments, to acquire KAI and its development programs, including etelcalcetide. [4]
The relevant patent categories are:
Composition and peptide patents
These protect the specific calcimimetic peptide structure, sequence, conjugation, or related chemical forms. Composition claims generally provide the strongest protection because they can block commercial use of the active ingredient regardless of a particular dosing regimen.
Manufacturing patents
These can cover peptide synthesis, purification, conjugation, control of impurities, and preparation of pharmaceutical-grade material. Manufacturing patents may remain commercially relevant after a composition patent expires if a competing manufacturer cannot readily reproduce the product using a non-infringing process.
Formulation and injectable-product patents
Formulation claims can cover concentration, excipients, stability, container systems, and injectable presentations. Their practical value depends on whether a generic or follow-on applicant must use the protected formulation to satisfy the FDA product requirements.
Method-of-use patents
Method claims may cover treatment of secondary hyperparathyroidism in hemodialysis patients, dose titration, administration after dialysis, or management of parathyroid hormone and calcium levels. These claims can create litigation exposure but are generally more vulnerable to design-around strategies than composition claims.
What is the Orange Book status of Parsabiv?
Parsabiv is approved under NDA 208325. The FDA Orange Book is the controlling public source for listed patents and approved product information. [5]
Etelcalcetide is not a conventional small-molecule tablet. Any abbreviated application would face technical and regulatory issues involving peptide identity, impurities, aggregation, stability, sterile manufacturing, and bioequivalence or pharmaceutical equivalence. A generic applicant could pursue an ANDA if the FDA determines that the product and route meet the applicable statutory requirements, but the development pathway is more complex than for standard oral cinacalcet.
The commercial effect is important: patent expiry alone may not produce immediate generic substitution. A prospective competitor would also need:
- A reliable peptide manufacturing process.
- Sterile injectable production.
- A validated analytical package.
- Adequate stability data.
- FDA approval of the proposed dosage form.
- Dialysis-provider contracting and supply capability.
When does etelcalcetide lose exclusivity?
FDA regulatory exclusivity began with the 2017 approval. If Parsabiv received five-year new chemical entity exclusivity, that period would have ended in 2022. Regulatory exclusivity and patent protection are separate. A generic or competing product may remain blocked after regulatory exclusivity expires if valid, enforceable patents cover the active ingredient, formulation, use, or manufacturing process.
The practical loss-of-exclusivity sequence is therefore likely to involve three stages:
| Stage |
Commercial implication |
| Regulatory exclusivity expiry |
Abbreviated applications can be filed if other requirements are satisfied |
| Patent challenge or expiry |
Litigation risk and potential approval timing become central |
| First commercial launch |
Dialysis contracts and pricing determine erosion speed |
The most important patent date is not necessarily the earliest expiration in the portfolio. The relevant date is the latest enforceable patent that covers a commercially usable etelcalcetide product or its required manufacturing process.
Which companies are challenging etelcalcetide?
Publicly visible competition is stronger on the therapeutic side than on the product-specific patent-challenge side. Generic-drug manufacturers compete with etelcalcetide indirectly through cinacalcet. The generic cinacalcet market has reduced the opportunity for Parsabiv to raise price without losing share.
No biosimilar pathway applies to etelcalcetide. It is a chemically defined peptide drug, not a therapeutic protein regulated through the U.S. biosimilar pathway under section 351(k) of the Public Health Service Act. A competing etelcalcetide product would more likely use an abbreviated or full drug-application route, depending on FDA determinations concerning sameness, complexity, and product characterization.
How strong is the etelcalcetide patent estate?
The estate has meaningful protection because etelcalcetide is a specialized peptide injectable rather than a simple oral small molecule. That strength has limits.
Factors supporting patent strength
- Complex peptide identity and conjugation.
- Sterile injectable manufacturing requirements.
- Limited number of likely qualified manufacturers.
- Potential overlap among composition, formulation, and process claims.
- High switching friction within dialysis-center protocols.
Factors weakening commercial exclusivity
- Generic cinacalcet is an established substitute.
- Method-of-use claims may be avoidable.
- Dialysis providers have strong purchasing leverage.
- A competitor does not need to replicate every commercial advantage to pressure price.
- Product-level revenue is concentrated in a narrow clinical population.
The estate is commercially stronger against a direct etelcalcetide copy than against therapeutic substitution by inexpensive oral calcimimetics.
What litigation and settlement risks affect Parsabiv?
The principal litigation risk is likely to arise from an abbreviated application asserting invalidity, non-infringement, or unenforceability of listed patents. A Paragraph IV filing could trigger patent litigation under the Hatch-Waxman framework and potentially delay approval through the statutory stay.
Relevant litigation issues would include:
- Whether the proposed peptide is the same active ingredient.
- Whether the proposed injectable formulation falls within listed claims.
- Whether process patents can be infringed by manufacturing outside the United States.
- Whether method-of-use claims are sufficiently specific.
- Whether patent claims are enabled and adequately described.
- Whether the applicant can launch with a label that omits protected uses.
Settlement terms could include a later-entry date, a license, manufacturing restrictions, or a contingent launch tied to patent litigation outcomes. No specific settlement should be assumed without a filed court order, FDA record, or company disclosure.
What generic launch scenarios exist for etelcalcetide?
Early direct competition
A successful direct competitor enters after resolving patent disputes and secures contracts with large dialysis operators. Price erosion would likely be faster in institutional accounts than in fragmented outpatient markets.
Delayed direct competition
Patent litigation or manufacturing complexity delays entry. Parsabiv retains share while generic cinacalcet continues to cap pricing.
Therapeutic substitution without direct entry
Generic cinacalcet expands further, reducing Parsabiv demand even without an etelcalcetide copy. This is the most immediate competitive pressure.
Limited regional competition
A competitor enters selected countries where patent protection, reimbursement, or local manufacturing economics are less restrictive. U.S. erosion remains limited until a U.S.-approved product launches.
What is the commercial outlook for etelcalcetide?
Parsabiv has a defensible but narrow commercial position. Its value comes from administration during dialysis, adherence control, and integration with facility workflows. Its primary vulnerability is the availability of low-cost generic cinacalcet, not a near-term biosimilar threat.
The likely financial trajectory is mature and reimbursement-sensitive:
- Growth depends on conversion from oral therapy.
- Volume is tied to the hemodialysis population and treatment rates.
- Pricing is constrained by dialysis-provider bargaining power.
- Direct generic entry would create a sharper decline than ordinary therapeutic substitution.
- Amgen’s acquisition economics depend on cumulative cash generation rather than blockbuster-scale revenue.
Key Takeaways
- Etelcalcetide is Amgen’s intravenous calcimimetic for secondary hyperparathyroidism in adult hemodialysis patients.
- Parsabiv’s strongest commercial advantage is controlled administration during dialysis.
- Generic cinacalcet is the principal competitive and pricing threat.
- The product has no biosimilar pathway because it is a peptide drug rather than a biologic subject to section 351(k).
- Direct competition is constrained by peptide characterization, sterile manufacturing, and dialysis-center contracting.
- Regulatory exclusivity has expired, but patent and manufacturing barriers remain commercially relevant.
- Direct generic entry would likely produce greater revenue erosion than gradual substitution by generic cinacalcet.
- Amgen’s public disclosures provide limited standalone information on Parsabiv revenue, margins, and geographic performance.
Frequently Asked Questions
Is etelcalcetide a biologic drug?
Etelcalcetide is a synthetic peptide drug. It is not generally treated as a biosimilar reference product under the U.S. 351(k) pathway.
Is Parsabiv stronger than Sensipar?
Parsabiv offers controlled intravenous administration during dialysis. Sensipar and generic cinacalcet offer oral dosing and generally lower acquisition cost. The preferred product depends on adherence, calcium control, facility workflow, and reimbursement.
Can generic manufacturers copy etelcalcetide?
They may be able to develop a competing product, but peptide manufacturing, sterile injectable production, analytical characterization, and patent disputes create greater barriers than those associated with ordinary generic tablets.
Does etelcalcetide have orphan-drug exclusivity?
Etelcalcetide was approved for a defined dialysis population, but the principal commercial protection should be evaluated through its FDA exclusivity designation and listed patents rather than assumed orphan-drug status.
What would most damage Parsabiv revenue?
The largest risks are expanded use of generic cinacalcet, unfavorable dialysis reimbursement, loss of facility formulary access, and approval of a direct etelcalcetide competitor.
References
- U.S. Food and Drug Administration. (2017). Parsabiv (etelcalcetide) prescribing information.
- Amgen Inc. (2024). 2023 annual report.
- Amgen Inc. (2023). 2022 annual report.
- Amgen Inc. (2015). Amgen to acquire KAI Pharmaceuticals.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
